Tags · Access
personal import
Rules on importing for personal use, which vary enormously.
Related in this group: insurance · prior authorisation · appeals · formulary · cost per milligram · compounding · shortage · NHS · EMA · FDA · MHRA · telehealth
52 topics · page 2 of 2
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Revisiting: German, French and Dutch differences, compared
Posting this under the heading it deserves: Revisiting: German, French and Dutch differences, compared Everything below is what sits behind that. A coverage question with the paperwork detail included, since…
|
+90 | 99 | 32k | 9mo |
|
About the European Union category
EMA positions, national differences within the EU, and cross-border purchase rules. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
|
+1 | 5 | 18k | 10mo |
|
EU-wide position versus national implementation
EU-wide position versus national implementation Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this category…
|
+22 | 29 | 356 | 11mo |
|
Cross-border purchase within the EU: the actual rules
Cross-border purchase within the EU: the actual rules Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is…
|
+6 | 10 | 41k | 11mo |
|
Second pass at: Import rules for personal quantities, by jurisdiction, dated
Second pass at: Import rules for personal quantities, by jurisdiction, dated Writing it up because I had to work it out twice and would rather nobody else did. A logistics question, since the answers here are…
|
2 | 5k | 11mo | |
|
Coming back to: Cross-border purchase rules within the EU
Cross-border purchase rules within the EU Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what…
|
+12 | 16 | 2.8k | 11mo |
|
Revisiting: Why a compound being unapproved is not the same as being illegal to possess
On the subject in the title: Revisiting: Why a compound being unapproved is not the same as being illegal to possess Working notes rather than a conclusion. Structured report rather than an opinion, following…
|
+76 | 82 | 52k | 11mo |
|
Import rules for personal quantities, by jurisdiction, dated
On the subject in the title: Import rules for personal quantities, by jurisdiction, dated Working notes rather than a conclusion. Structured report rather than an opinion, following the format the maintainers…
|
3 | 60k | 12mo | |
|
Second pass at: Pharmacy supply in the UK and the questions you will be asked
Second pass at: Pharmacy supply in the UK and the questions you will be asked Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail…
|
+46 | 53 | 14k | 12mo |
|
Reading a regulatory notice rather than an article about it — what changed since
Reading a regulatory notice rather than an article about it — what changed since — setting out what I have, and where I think it stops being reliable. A logistics question, since the answers here are usually…
|
+28 | 32 | 640 | 13mo |
|
UK access routes, dated and sourced — a second dataset
Posting this under the heading it deserves: UK access routes, dated and sourced — a second dataset Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this…
|
+76 | 82 | 25k | 14mo |
|
Enforcement priorities versus written rules
Enforcement priorities versus written rules — setting out what I have, and where I think it stops being reliable. I would like to talk about documentation quality as a signal, separately from product quality.…
|
2 | 62k | 15mo | |
|
UK access routes, dated and sourced
UK access routes, dated and sourced Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this category expires. As of…
|
2 | 5.8k | 15mo | |
|
Second pass at: Cross-border purchase within the EU: the actual rules
Posting this under the heading it deserves: Second pass at: Cross-border purchase within the EU: the actual rules Everything below is what sits behind that. Documenting an access outcome, dated, because…
|
+135 | 139 | 8.7k | 16mo |
|
How compounding permissions changed when supply normalised
Asking directly, because I could not find a straight answer: How compounding permissions changed when supply normalised Structured report rather than an opinion, following the format the maintainers asked…
|
+30 | 34 | 51k | 16mo |
|
What changed in 2026, by region
What changed in 2026, by region — that is the question, and I have not found it answered plainly anywhere I have looked. Documenting an access outcome, dated, because everything in this category expires. As…
|
+110 | 122 | 1.4k | 18mo |
|
[2026 update] EU-wide position versus national implementation
On the subject in the title: EU-wide position versus national implementation Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of…
|
2 | 54k | 19mo | |
|
Coming back to: Research-use-only labelling: what it means and what it does not
Research-use-only labelling: what it means and what it does not — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the…
|
+45 | 50 | 39k | 20mo |
|
EMA product information as a primary source — does this still hold?
The question in the title: EMA product information as a primary source — does this still hold? I will give what I have already checked below so nobody repeats it. Documenting an access outcome, dated, because…
|
+127 | 150 | 41k | 20mo |
|
Second pass at: Reimbursement variation across member states
On the subject in the title: Second pass at: Reimbursement variation across member states Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what…
|
+23 | 28 | 45k | 21mo |
|
About the International category
Country-by-country availability and legality, dated because it changes constantly. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
|
+6 | 11 | 240 | 22mo |
|
MHRA statements, read directly — the long version
On the subject in the title: MHRA statements, read directly — the long version Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of…
|
2 | 44k | 22mo |